<DOC>
	<DOCNO>NCT00619762</DOCNO>
	<brief_summary>This prospective , multicenter , open-label study assess clinical outcome LTM product three planned analysis . The primary objective study prospectively assess clinical outcome associate use LTM two-stage ( expander permanent implant ) immediate post-mastectomy breast reconstruction .</brief_summary>
	<brief_title>Immediate Postmastectomy Breast Reconstruction ( Strattice Breast )</brief_title>
	<detailed_description>nothing add</detailed_description>
	<criteria>A candidate immediate , twostage breast reconstruction use LTM follow skin spar mastectomy An ASA Physical Status Classification5 1 2 ( see App I ) Estimated life expectancy &gt; 1 year Clinically significant systemic disease Received inductive chemotherapy within 2 month prior mastectomy radiation therapy region time Predicted excised breast mass &gt; 750 gms Comorbid factor predispose postoperative infection , insulin dependent diabetes , smoking , chronic steroid use , malnourishment , coexistent infection Need tissue flap addition expander History alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , drug abuse addiction Enrollment plan enroll another clinical trial study would affect patient 's safety result trial Any condition identify within labeled contraindication , i.e . sensitivity porcine derive product polysorbate</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast reconstruction</keyword>
</DOC>